My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 716

    1.

    Clinical trials in severe sepsis with drotrecogin alfa (activated).

    Laterre PF.

    Crit Care. 2007;11 Suppl 5:S5. Review.PMID: 18269692 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

    Barie PS, Hydo LJ, Shou J, Eachempati SR.

    Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.PMID: 16895513 [PubMed - indexed for MEDLINE]Related articles

    3.

    From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

    Short MA, Schlichting D, Qualy RL.

    Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.PMID: 17265595 [PubMed - indexed for MEDLINE]Related articles

    4.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61. PMID: 17084715 [PubMed - indexed for MEDLINE]Related articles

    5.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.PMID: 16192478 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.PMID: 12544987 [PubMed - indexed for MEDLINE]Related articles

    7.

    Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

    Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

    Chest. 2004 Jun;125(6):2206-16.PMID: 15189943 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

    9.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.PMID: 17431957 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).

    Rudis MI, Fish DN.

    Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. Review.PMID: 12492225 [PubMed - indexed for MEDLINE]Related articles

    11.

    Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

    McCoy C.

    Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.PMID: 15500421 [PubMed - indexed for MEDLINE]Related articles

    12.

    Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

    De Backer D.

    Drug Saf. 2007;30(11):995-1010. Review.PMID: 17973539 [PubMed - indexed for MEDLINE]Related articles

    13.

    Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

    Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

    Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.PMID: 12720562 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.PMID: 15640631 [PubMed - indexed for MEDLINE]Related articles

    15.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.PMID: 18786266 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The safety profile of drotrecogin alfa (activated).

    Fumagalli R, Mignini MA.

    Crit Care. 2007;11 Suppl 5:S6. Review.PMID: 18269693 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

    Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL.

    J Crit Care. 2007 Jun;22(2):142-52. Epub 2007 Jan 31.PMID: 17548026 [PubMed - indexed for MEDLINE]Related articles

    18.

    Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

    [No authors listed]

    Prescrire Int. 2007 Feb;16(87):7-9.PMID: 17323514 [PubMed - indexed for MEDLINE]Related articles

    19.

    Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.

    Bernard GR.

    Crit Care Med. 2003 Jan;31(1 Suppl):S85-93. Review.PMID: 12544981 [PubMed - indexed for MEDLINE]Related articles

    20.

    Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.

    Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF; PROWESS Clinical Evaluation Committee.

    Crit Care Med. 2005 May;33(5):952-61.PMID: 15891319 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity